open access

Vol 83, No 5 (2012)
ARTICLES
Get Citation

Clinical features and disease course in patients with BRCA1-dependent ovarian cancer

Paweł Blecharz, Wiktor Szatkowski, Maciej Bodzek, Elżbieta Łuczyńska
Ginekol Pol 2012;83(5).

open access

Vol 83, No 5 (2012)
ARTICLES

Abstract

f the disease and prognosis of BRCA1-dependent OC vary between sporadic cases. Aim of the study: To analyze clinical features and disease courses of BRCA1-dependent OC in the material from Center of Oncology, Cracow Branch. Material and methods: Between 2004 and 2008, 66 mutations of BRCA1 gene were found in patients with OC. All patients were treated with primary surgery followed by platinum-based chemotherapy. Outcomes were assessed by means of clinical examination and imaging tests. Patients with complete response were followed up in the outpatient office. Secondary chemotherapy was administered if persistent or progressive disease was diagnosed. Results: In the analyzed group of 66 (100%) patients, the following mutations of BRCA1 gene were found: in 31 (47%) – C61G (exon 5), in 21 (31,8%) – 5382insC (exon 20), in 6 (9.1%) – 185delAG and in 8 (12.1%) – other (exon 11). Mean patient age was 48. FIGO stage I and stage II were diagnosed in 7 (10,6%), stage III in 58 (89,9%) and stage IV in 1 patient (1,5%). Twenty five (37.9%) patients underwent complete macroscopic primary cytoreduction. Platinum-based chemotherapy was administered to all 66 patients after surgery. Complete response (CR), partial response (PR) and progressive disease (PD) was achieved in 31 (46.9%), 30 (45,5%) and 5 (7.6%) patients, respectively. Secondary surgery was performed in 29 (43.9%) of patients after completion of adjuvant therapy. Second-line chemotherapy was administered in 40 (60.6%) patients due to residual or progressive disease. Mean time of follow-up was 65 months. Forty one (62.1%) patients died due to OC progression. Conclusions: Clinical features and disease courses in BRCA1-dependent OC patients in the analyzed group were similar to other results reported in the literature.

Abstract

f the disease and prognosis of BRCA1-dependent OC vary between sporadic cases. Aim of the study: To analyze clinical features and disease courses of BRCA1-dependent OC in the material from Center of Oncology, Cracow Branch. Material and methods: Between 2004 and 2008, 66 mutations of BRCA1 gene were found in patients with OC. All patients were treated with primary surgery followed by platinum-based chemotherapy. Outcomes were assessed by means of clinical examination and imaging tests. Patients with complete response were followed up in the outpatient office. Secondary chemotherapy was administered if persistent or progressive disease was diagnosed. Results: In the analyzed group of 66 (100%) patients, the following mutations of BRCA1 gene were found: in 31 (47%) – C61G (exon 5), in 21 (31,8%) – 5382insC (exon 20), in 6 (9.1%) – 185delAG and in 8 (12.1%) – other (exon 11). Mean patient age was 48. FIGO stage I and stage II were diagnosed in 7 (10,6%), stage III in 58 (89,9%) and stage IV in 1 patient (1,5%). Twenty five (37.9%) patients underwent complete macroscopic primary cytoreduction. Platinum-based chemotherapy was administered to all 66 patients after surgery. Complete response (CR), partial response (PR) and progressive disease (PD) was achieved in 31 (46.9%), 30 (45,5%) and 5 (7.6%) patients, respectively. Secondary surgery was performed in 29 (43.9%) of patients after completion of adjuvant therapy. Second-line chemotherapy was administered in 40 (60.6%) patients due to residual or progressive disease. Mean time of follow-up was 65 months. Forty one (62.1%) patients died due to OC progression. Conclusions: Clinical features and disease courses in BRCA1-dependent OC patients in the analyzed group were similar to other results reported in the literature.
Get Citation

Keywords

ovarian cancer, BRCA1 mutation, Clinical features

About this article
Title

Clinical features and disease course in patients with BRCA1-dependent ovarian cancer

Journal

Ginekologia Polska

Issue

Vol 83, No 5 (2012)

Bibliographic record

Ginekol Pol 2012;83(5).

Keywords

ovarian cancer
BRCA1 mutation
Clinical features

Authors

Paweł Blecharz
Wiktor Szatkowski
Maciej Bodzek
Elżbieta Łuczyńska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl